Advocacy News

Statement of Lymphoma Research Foundation on Access to Treatment

Policymakers in Washington, DC, and state capitols are considering measures to address the cost of health care, including prescription drugs, and to address insurance adequacy issues.  As debate on these initiatives intensifies, we urge that policymakers consider the needs of people with lymphoma and lymphoma survivors. 

LRF Advocates for Patient Access to Cellular Therapies

On November 2, 2019, the Lymphoma Research Foundation sent a letter to Donald Thompson, Director, Division of Acute Care at the Centers for Medicare and Medicaid Services requesting for MS-DRG reclassification for certain cases involving the use of chimeric antigen receptor T-cell (CAR T-cell) therapies.